Zafgen Inc (NASDAQ:ZFGN) has analysts on the Bullish side this week.

June 19, 2017 - By Marry Poplack

 Zafgen Inc (NASDAQ:ZFGN) has analysts on the Bullish side this week.

Zafgen Inc (NASDAQ:ZFGN) Ratings Coverage

Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc had 17 analyst reports since August 25, 2015 according to SRatingsIntel. RBC Capital Markets maintained Zafgen Inc (NASDAQ:ZFGN) rating on Thursday, October 15. RBC Capital Markets has “Outperform” rating and $46 target. The firm has “Neutral” rating by Suntrust Robinson given on Thursday, December 3. FBR Capital maintained it with “Outperform” rating and $48 target in Thursday, October 15 report. FBR Capital downgraded Zafgen Inc (NASDAQ:ZFGN) on Wednesday, July 20 to “Mkt Perform” rating. RBC Capital Markets upgraded the shares of ZFGN in report on Thursday, January 21 to “Outperform” rating. On Friday, January 6 the stock rating was upgraded by JMP Securities to “Mkt Outperform”. On Wednesday, July 20 the stock rating was downgraded by Cowen & Co to “Market Perform”. The firm has “Buy” rating by Cowen & Co given on Tuesday, August 25. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, December 2. Canaccord Genuity maintained Zafgen Inc (NASDAQ:ZFGN) on Friday, November 13 with “Buy” rating. Below is a list of Zafgen Inc (NASDAQ:ZFGN) latest ratings and price target changes.

06/01/2017 Broker: JMP Securities Old Rating: Mkt Perform New Rating: Mkt Outperform Upgrade

It closed at $3.64 lastly. It is down 36.39% since June 19, 2016 and is downtrending. It has underperformed by 53.09% the S&P500.

Zafgen, Inc. is a biopharmaceutical company. The company has market cap of $98.29 million. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. It currently has negative earnings. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: which released: “Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment …” on June 10, 2017, also with their article: “Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second …” published on May 04, 2017, published: “Zafgen Reports First Quarter 2017 Financial Results” on May 09, 2017. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: and their article: “Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of …” published on September 20, 2016 as well as‘s news article titled: “Zafgen to Present at the JMP Securities Life Sciences Conference” with publication date: June 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.